Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Therapeutic method to treat prostate carcinomas by administration of cellular PAcP protein. More
Novel target and monoclonal antibody for early diagnosis and/or therapeutic intervention More
This antibody is specific for the TCR CD3 epsilon chain and can also be used to identify this subunit in immunoprecipitation and immunoblotting applications More
Diagnostic assay for early detection of nephropathy related to diabetes and other nephropathy-associated disorders. More
A neuron-specific tau kinase involved in tau hyperphosphorylation and aggregation. More
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
Recently characterized MUC17 gene highly specific for pancreatic cancer. More
Diagnostic and potential therapeutic applications for mucin gene 4 (MUC4). More
The University of Edinburgh, in collaboration with the SNBTS, Roslin Institute Neuropathogenesis Unit, and the University of Strathclyde, has developed an antibody that can distinguish abnormal PrP (PrPSc) from the normal cellular form (PrPC) More
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us